Grundinformationen
- CAS
13009-99-9- Standard-SMILES
CC(=O)O.NCc1ccc(S(N)(=O)=O)cc1- InChIKey
UILOTUUZKGTYFQ-UHFFFAOYSA-N- Summenformel
- C9H14N2O4S
- Durchschnittliche Molmasse
- 246,29 g/mol
- Monoisotopische Masse
- 246,06742793
Überblick
Mafenide acetate is a carboxylic acid.
Namen und Bezeichner
- Bevorzugter Name
- Mafenide Acetate
- IUPAC
- acetic acid;4-(aminomethyl)benzenesulfonamide
- Lokaler Name
- α-Aminotoluol-4-sulfonamidmonoacetat
- Englischer Name
- Mafenide acetate
- Summenformel
- C9H14N2O4S
- Molmasse
- 246.28
Namen und Synonyme
MAFENIDE ACETATE13009-99-9SulfamilonBenzenesulfonamide, 4-(aminomethyl)-, monoacetateRQ6LP6Z0WYalpha-Amino-p-toluenesulfonamide monoacetate4-(Aminomethyl)benzenesulfonamide monoacetateDTXSID00156334RefChem:55527DTXCID0078825NSC346324-(AMINOMETHYL)BENZENESULFONAMIDE ACETATE
Weitere Namen anzeigen
MAFENIDEMefamideMARFANILmaphenideacetateSulfamylon AcetateMafenidine AcetateMAFENAMIDE ACETATESulfamimeron acetate
Mafenide (Acetate)MFCD00072089Benzenesulfonamide, 4-(aminomethyl)-, acetate (1:1)acetic acid;4-(aminomethyl)benzenesulfonamideMafatateMafenide acetate (JAN/USP)MAFENIDE ACETATE [MI]HMS2231M06
Datenbank-Bezeichner
- CAS
13009-99-9- PubChem CID
- 25590
Eigenschaften
Berechnete Struktureigenschaften
- Polarare Oberfläche (TPSA)
- 132 Ų
- H-Brücken-Donoren
- 3
- H-Brücken-Akzeptoren
- 6
- Frei drehbare Bindungen
- 2
- Schwere Atome
- 16
- Formalladung
- 0
- Komplexität
- 255
Experimentelle und physikochemische Eigenschaften
Solubility>36.9 [ug/mL] (The mean of the results at pH 7.4)
Human Drugs
FDA approved drugs -> Active ingredient
FDA approved drugs -> Active ingredient
Physikochemische Eigenschaften
- Schmelzpunkt
- 151 · 151-152°C
- storage temp.
- 2 · Inert atmosphere,2-8°C
- Löslichkeit
- 1 mg/mL · DMSO: soluble1mg/mL
- Aggregatzustand
- Solid
- Farbe
- white
- InChI
- InChI=1S/C7H10N2O2S.C2H4O2/c8-5-6-1-3-7(4-2-6)12(9,10)11;1-2(3)4/h1-4H,5,8H2,(H2,9,10,11);1H3,(H,3,4)
- InChIKey
- UILOTUUZKGTYFQ-UHFFFAOYSA-N
- SMILES
- C1(=CC=C(CN)C=C1)S(=O)(=O)N.C(=O)(O)C
- CAS Datenbank
- 13009 · 13009-99-9(CAS DataBase Reference)
Sicherheit und Regulatorisches
Sicherheitsangaben dienen nur zur Orientierung und ersetzen weder das Sicherheitsdatenblatt (SDB) des Lieferanten noch geltende Vorschriften oder eine fachliche Bewertung.
GHS-Klassifizierung
GHS Classification
Warning
H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]
P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)
Aggregated GHS information provided per 2 reports by companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
Gefahrenhinweise
Hazard Classes and CategoriesAcute Tox. 4 (100%)
Sicherheitsdaten
- wgk
- 3
- hs_code
- 2935904000
- Toxizität
- LD50 in rats, mice (mg/kg): 2040, 1580 i.v. (Skulan, Hoppe)
- hazard_class
- IRRITANT
- Speicherklasse
- 11 - Combustible Solids
Chemie und Industrie
Pharmakologische Informationen
FDA Pharmacological Classification
MAFENIDE ACETATE
Methylated Sulfonamides [EXT]; Methylated Sulfonamide Antibacterial [EPC]
MeSH Pharmacological Classification
Substances used on humans and other animals that destroy harmful microorganisms or inhibit their activity. They are distinguished from DISINFECTANTS, which are used on inanimate objects.
A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES.
Substances that inhibit the growth or reproduction of BACTERIA.
Anwendungen
BeschreibungMafenide Acetate, also known sulfamylon acetate, is a topical sulphonamide antimicrobial agent with activity against a wide range of microorganisms commonly associated with burn wound infections, including Pseudomonas aeruginosa and Staphylococcus aureus. It is primarily used for the prevention and treatment of burn wound infections. As a carbonic anhydrase inhibitor, sulfamylon acetate may cause metabolic acidosis and peripheral vasodilation. Therefore, its concomitant use with hyperbaric oxygen therapy should be carefully assessed. In burn patients requiring hyperbaric oxygen therapy, silver sulfadiazine may be considered as an alternative topical antimicrobial agent.
Vor- und nachgelagerte Produkte
Vorgelagerte Rohstoffe
Anbieter100 Anbieter
Zugehörige Reaktionen
1
Notizen zur Verbindung
Wird geladen…